摘要
目的:系统评价利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的药物经济学价值。方法:用计算机检索PubMed、ScienceDirect、Springer Link、Elsevier等英文数据库以及CNKI、维普、万方等中文数据库1998—2013年间公开发表的利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的药物经济学评价文献,对文献质量、研究结果进行系统评价。结果:所有英文文献的ICER值均在各国的意愿支付范围内;国内外利妥昔单抗药物经济学评价在数据来源、研究方法等方面存在差异。结论:利妥昔单抗联合化疗治疗非霍奇金淋巴瘤在国外具有成本-效果;需开展高质量的研究来探索利妥昔单抗联合化疗治疗非霍奇金淋巴瘤在我国的经济性。
Objective： To systematically evaluate the pharmacoeconomic value of the combined use of rituximab and chemotherapy for the treatment of non-hodgkin＇s lymphoma （NHL）. Methods： Literatures of the pharmacoeconomics evaluation on the combined use of rituximab and chemotherapy for the treatment of NHL in 1998-2013 were retrieved from the international and domestic online databases including Pubmed, ScienceDirect, Springer Link, Elseviers, CNKI, CQVIP and Wanfang Data. The literatures were evaluated systematically in terms of the quality and research results. Results： The ICER values from the literatures of English were all within the range of the willingness-to-pay （WTP） of each country. Also, in terms of data sources and researching methods, the domestic and international pharmacoeconomic studies of the combined use of rituximab and chemotherapy for the treatment of NHL varied from each other. Conclusion： The treatment of NHL with the combined use of rituximab and chemotherapy is cost-effective in foreign country; the pharmaceutical evaluation studies with high quality are needed to explore the domestic economical efficiency of chemotherapy combined with rituximab for the treatment of NHL.
出处
《药学进展》
CAS
2014年第5期362-369,共8页
Progress in Pharmaceutical Sciences
